Award details

Commercializing Abysis - an integrated resource for storing and analyzing antibody sequence and structure

Reference	BB/K015443/1
Principal Investigator / Supervisor	Professor Andrew Martin
Co-Investigators / Co-Supervisors
Institution	University College London
Department	Structural Molecular Biology
Funding type	Research
Value (£)	161,293
Status	Completed
Type	Research Grant
Start date	13/05/2013
End date	31/10/2014
Duration	18 months

Abstract

unavailable

Summary

Around 1/3rd of drugs in development are now monoclonal antibodies (mAbs) with >30 clinically approved. However many fail during development often because they create an immune reaction in the patient. Even newer 'fully human' mAbs can be immunogenic. We will enhance Abysis, our prototype software for storing and analyzing antibody sequence and structure, to allow wide used by pharmaceutical companies enabling production of better antibody-based biotherapeutics. The resource links DNA and protein sequence and structure to aid in developing therapeutic antibodies. We will enhance the interface and underlying code to make the system easier to maintain and install. The software will be modified to work more effectively with unusual antibodies from camel, llama, shark and chicken, which are now of interest to drug companies. We will link unusual sequence features to structure allowing identification of regions of antibodies that may be responsible for generating an immune response.

Committee	Not funded via Committee
Research Topics	Immunology, Pharmaceuticals, Structural Biology, Technology and Methods Development
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search